messaggio
clik on the image and visit the new site
"In silico"
From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".
In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson
Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.
Phage Therapy is influenced by:
Phage therapy is influenced by:
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail
My point of view
Sunday 31 January 2010
L5 mycobacterium phage repressor
From :
Transcriptional silencing by the mycobacteriophage L5 repressor
I have verified if the L5 gp71 protein is a protein (183 Aa) with a binding capacity to the DNA.
See:
Helix-turn-helix
Basic-helix-loop-helix
DNA-binding protein
I have used mEMBOSS software (open source)for finding the part of the protein with a binding capacity:
"FNQTEIAELYGVTRQAVSWHKK"
This is the primary and secondary structure of L5 gp 71 repressor:
Labels:
L5 mycobacterium phage repressor